Skip to content

Development of Non-invasive Methods to Study Gut Microbiome - Nutrition - Host Interactions

Development of Non-invasive Methods to Study Gut Microbiome - Nutrition - Host Interactions

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05949411
Enrollment
100
Registered
2023-07-18
Start date
2023-07-01
Completion date
2024-12-31
Last updated
2023-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The aim of this study is to develop and validate an adequate protocol of volatolome (volatile metabolites) measurement in breath of human volunteers (18-65 years) to study gut microbiome - nutrition - host interactions in a general healthy population. For this purpose, breath volatile metabolites (BVM) will be analyzed throughout test days in fasting state and after standardized meals using selected ion flow tube mass spectrometry (SIFT-MS). In addition, gut microbial functions linked notably to hydrogen/methane production, carbohydrates utilization (CAZymes), and in the production of other volatile metabolites of interest (i.e. indole, fatty acid derivatives, ...) will be unraveled through microbiome sequencing data analysis (in silico), metabolomic analyses and measurement of enzymatic activities from saliva, urine and/or fecal samples.

Interventions

Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.

OTHERLactulose test

Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.

OTHERAdministration of standardized meals with characterized dietary fiber content

Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.

Sponsors

Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Woman or man, aged of 18 to 65 years; * Body mass index (BMI) between 18 and 30 kg/m2; * Non-smoker; * Provision of signed and dated informed consent form; * Stated willingness to comply with all study procedures and availability for the duration of the study; * Speaking French.

Exclusion criteria

* Subject with severe systemic disease (renal or hepatic failure, cancer, pancreatic cancer, chronic pancreatitis, asthma …) * Subject with a history or current chronic/severe gastrointestinal disorder such as duodenal ulcer, chronic colitis, or chronic inflammatory disease of the digestive tract disease (Crohn's disease, ulcerative colitis), celiac disease or irritable bowel syndrome; * Subjects with a history of digestive tract surgery (except appendectomy); * Subject who had surgery within the two months prior to the study * Subjects with psychiatric problems and/or using antipsychotics * Current or recent (\< 4 weeks) intake of antibiotics, fiber supplement, and/or any products modulating gut transit (laxative, anti-diarrheal, ...) or gut microbiota composition; these products will also be avoided for the duration of the study; * Chronic intake of drugs, except contraceptive drug; * Subject following a low-calorie diet and followed by a doctor or dietician in progress or recently (\< 6 weeks); * Women of childbearing age who are pregnant or breastfeeding or who wish to become pregnant within the next 6 weeks or who are not using an adequate method of contraception (e.g. oral contraception, intrauterine device (IUD), abstinence, ...); * Subjects who drink more than 3 glasses of alcohol per day (\> 30 g of alcohol per day); * Subjects having participated to another clinical trial two weeks before the screening test visit; * Subjects who practice an intense sport activity (more than 10 hours per week of intense activity); * Language barrier, mental or legal incapacity, unwillingness or inability to understand or not being able to participate to the study.

Design outcomes

Primary

MeasureTime frameDescription
Exhaled volatile compoundsThroughout the entire study, approximately during 24 monthsSelected Ion flow tube mass spectrometry (SIFT-MS) - Area under the curve (calculated on 8 hours following breakfast ingestion)

Secondary

MeasureTime frameDescription
Transit - level of emergencyThroughout the entire study, approximately during 24 months5-point Likert's scale (1 = very urgent need to defecate, 5 = very nonurgent need to defecate)
Gut microbiotaThroughout the entire study, approximately during 24 monthsIllumina sequencing of 16S ribosomal deoxyribonucleic acid (rDNA), quantitative polymerase chain reaction (PCR)
Salivary microbiotaThroughout the entire study, approximately during 24 monthsIllumina sequencing of 16SrDNA, quantitative PCR
Gastrointestinal symptom - discomfortThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - nauseaThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - bloatingThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - flatulencesThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - gastrointestinal refluxThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - crampsThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - rumblingThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom) - Area under the curve (calculated on 8 hours following breakfast ingestion)
Gastrointestinal symptom - burpsThroughout the entire study, approximately during 24 months100 mm Visual analog scale (0 = no symptom, 100 = very severe symptom)
Transit - ease of passageThroughout the entire study, approximately during 24 months5-point Likert's scale (1 = very difficult to defecate, 5 = very easy to defecate)
Exhaled hydrogen (H2)Throughout the entire study, approximately during 24 monthsLactotest 202 - Area under the curve (calculated on 4 hours following lactulose ingestion)
Exhaled methane (CH4)Throughout the entire study, approximately during 24 monthsLactotest 202 - Area under the curve (calculated on 8 hours following breakfast ingestion)
Exhaled carbon dioxide (CO2)Throughout the entire study, approximately during 24 monthsLactotest 202 - Area under the curve (calculated on 4 hours following lactulose ingestion)
Carbohydrates utilization - Carbohydrate active enzymes (CAZymes)Throughout the entire study, approximately during 24 monthsSaliva enzymatic activities
Nutrient intakeThroughout the entire study, approximately during 24 monthsFood diary (daily log of what the volunteer eats and drinks each day)
Dietary habitsThroughout the entire study, approximately during 24 monthsFood frequency questionnaire (FFQ) (record the volunteers' usual diet and dietary habits)
Well-beingThroughout the entire study, approximately during 24 monthsThe short form (36) health survey (SF36) (0 = worse physical and mental health functioning, 100 = best physical and mental health functioning)
Transit - frequencyThroughout the entire study, approximately during 24 monthsQuestionnaire on stool frequency (record each defecation time)
Transit - type of stoolThroughout the entire study, approximately during 24 monthsBristol stools scale (BSS) (classify the form of feces into 7 categories; type 1 = severe constipation, type 2 = mild constipation, types 3 and 4 = normal, type 5 = lacking fiber, type 6 = mild diarrhea, type 7 = severe diarrhea)
Transit - empty feelingThroughout the entire study, approximately during 24 months5-point Likert's scale (1 = very nonempty feeling after defecation, 5 = very empty feeling after defecation)
Gut microbiota metabolic capacityThroughout the entire study, approximately during 24 monthsEnzymatic analysis via in-vitro studies, incubation of fecal extracts

Countries

Belgium

Contacts

Primary ContactNathalie Delzenne, Prof.
nathalie.delzenne@uclouvain.be0032 2 764 73 69

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 24, 2026